{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2021"],"condition":["Advanced Metastatic Colorectal Cancer","Colorectal Neoplasms"],"disease":["Advanced Metastatic Colorectal Cancer","Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2398610"],"location":["China"],"study_start_month":["11"],"keyword":["Raltitrexed","Irinotecan","First-line Treatment","Cetuximab","Bevacizumab"],"repository":["ECRIN MDR"],"study_status":["Recruiting"],"additional_accession":[]},"is_claimable":false,"name":"SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer","description":"The objective is to investigate the efficacy and safety of raltitrexed combined with Irinotecan (SALIRI) based regimen as first-line treatment for advanced metastatic colorectal cancer(mCRC).","dates":{"creation":"2021-11-15"},"accession":"2398610","cross_references":{"ClinicalTrials___gov":["NCT05160896"]}}